Martin Simkovic
Overview
Explore the profile of Martin Simkovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
1184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brown J, Seymour J, Jurczak W, Aw A, Wach M, Illes A, et al.
N Engl J Med
. 2025 Feb;
392(8):748-762.
PMID: 39976417
Background: Whether fixed-duration acalabrutinib-venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia (CLL) is unknown. Methods: In this phase...
2.
Shadman M, Munir T, Robak T, Brown J, Kahl B, Ghia P, et al.
J Clin Oncol
. 2024 Dec;
43(7):780-787.
PMID: 39647999
JCO SEQUOIA (ClinicalTrials.gov identifier: NCT03336333) is a phase III, randomized, open-label trial that compared the oral Bruton tyrosine kinase inhibitor zanubrutinib to bendamustine plus rituximab (BR) in treatment-naïve patients with...
3.
Ondrisova L, Seda V, Hlavac K, Pavelkova P, Hoferkova E, Chiodin G, et al.
J Clin Invest
. 2024 Oct;
134(23).
PMID: 39436708
Bruton tyrosine kinase (BTK) inhibitor therapy induces peripheral blood lymphocytosis in chronic lymphocytic leukemia (CLL), which lasts for several months. It remains unclear whether nongenetic adaptation mechanisms exist, allowing CLL...
4.
Brown J, Eichhorst B, Lamanna N, OBrien S, Tam C, Qiu L, et al.
Blood
. 2024 Sep;
144(26):2706-2717.
PMID: 39316666
The ALPINE trial established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; here, we present data from the final comparative analysis...
5.
Chatzikonstantinou T, Scarfo L, Minga E, Karakatsoulis G, Chamou D, Kotaskova J, et al.
Hemasphere
. 2024 Sep;
8(9):e70004.
PMID: 39290716
No abstract available.
6.
Vodarek P, Ecsiova D, Rezacova V, Soucek O, Simkovic M, Vokurkova D, et al.
Cancer Med
. 2024 Aug;
13(15):e7399.
PMID: 39119792
Introduction: The impact of chemoimmunotherapy (CIT) on immunoglobulin (Ig) quantities in patients with chronic lymphocytic leukemia (CLL) has not been extensively studied. Methods: We analyzed Ig levels in 45 stable...
7.
Polozsanyi Z, Galadova H, Kalinak M, Jopcik M, Kalinakova B, Breier A, et al.
Plants (Basel)
. 2024 Apr;
13(7).
PMID: 38611524
(hoary cress) is a perennial plant belonging to the family that produces two dominant glucosinolates (GLSs): glucoraphanin (GRN) and sinalbin (SBN). They represent the stored form, which is converted upon...
8.
Kater A, Owen C, Moreno C, Follows G, Munir T, Levin M, et al.
NEJM Evid
. 2024 Feb;
1(7):EVIDoa2200006.
PMID: 38319255
BACKGROUND: GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-venetoclax in older patients and/or those with comorbidities with previously untreated chronic lymphocytic leukemia (CLL). METHODS: We...
9.
Brown J, Eichhorst B, Hillmen P, Jurczak W, Kazmierczak M, Lamanna N, et al.
Future Oncol
. 2023 Dec;
20(12):717-726.
PMID: 38088119
What Is This Summary About?: This is a plain language summary of a research study called ALPINE. The study involved people who had been diagnosed with, and previously treated at...
10.
Chatzikonstantinou T, Scarfo L, Karakatsoulis G, Minga E, Chamou D, Iacoboni G, et al.
EClinicalMedicine
. 2023 Nov;
65:102307.
PMID: 38033506
Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed...